2 Canadian Marijuana Stocks to Avoid Besides CannTrust (TSX:TRST)

You’ve heard to avoid CannTrust Holdings Inc. (TSX:TRST)(NYSE:CTST), but I would also consider these other stocks.

| More on:

Things were going quite well for CannTrust Holdings (TSX:TRST)(NYSE:CTST) only a few months ago, when shares reached just over $13 and the business was booming. But as the cannabis industry started to slump, terrible news came out for this cannabis company.

Back in July, it was discovered by Health Canada that the company was using five unlicensed rooms to produce cannabis. These rooms have since been approved by Health Canada; however, it has put a lot of product on hold, and the company may receive a fine up to $1,000,000 or even lose its licence.

The scandal has been all over the news, which is why many are saying you should avoid it like the plague. But in this uncertain time in the marijuana industry, I would also consider avoiding these two other companies for the time being.

Hexo

While Hexo (TSX:HEXO)(NYSE:HEXO) may look promising in the near term, it’s the long term that investors should be thinking about when buying cannabis stocks. Does the company really have what it takes to produce for years, even decades to come? In Hexo’s case, I don’t believe so.

The company has received a lot of excitement lately over the edibles market. Hexo expects its profits to soar, with an increase of 452% in sales when edibles are legalized in Canada this October, with some products on the shelves by December. The company has been working with Molson Coors Canada to create cannabis-infused beverages and is even looking into everyday products to see how it could introduce cannabis-infused products to your grocery store.

Hexo believes it can do this after it launches its 600,000-square-feet facility space specifically meant for derivatives production, and through its five-year deal to supply cannabis to Quebec. However, if I were an investor I would wait to see how successful the derivatives market actually looks before investing in Hexo. There could be a lot of hype (see last year) for a whole lot of nothing. If that’s the case, Hexo could be sunk.

Cronos

A similar situation lies with Cronos Group (TSX:CRON)(NYSE:CRON) but within the cannabidiol (CBD) market. Like Hexo, this company has placed a lot on its bet that CBD will do well. The company has been growing immensely, mostly through acquisitions, with the funds it received from Altria a few months back. It’s generated a lot of excitement, as it looks like the company is continuing the grow, but does it warrant all that hype?

Cronos announced back in July it would be entering the United States CBD market, and it does look to be fairly lucrative according to Wall Street with value estimates of US$16 billion by 2025. This was followed by intentions to acquire Redwood Holding Group, an owner of popular CBD brand Lord Jones for US$300 million, giving it a place in the U.S.

So, while many investors are getting excited about Cronos’s future potential, it’s just that: potential. There really isn’t that much proof yet that CBD will be a huge move in the U.S. Meanwhile, Cronos is still trading fairly high, making now not a great time to invest in this company that is, frankly, still in set-up mode, with no plans for all of its cash on hand.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing.

More on Cannabis Stocks

Stethoscope with dollar shaped cord
Cannabis Stocks

Best Stock to Buy Right Now: Bausch Health vs Canopy Growth?

While both stocks are risky, Bausch Health is seeing operational momentum, while Canopy Growth is still struggling with losses.

Read more »

Worker checks cannabis flower in lab farm greenhouse
Cannabis Stocks

Down an Incredible 99% From All-Time Highs, Is Canopy Growth Stock Worth Buying Now?

Canopy Growth stock remains a high-risk investment in 2025 due to its weak balance sheet and volatile profit margins.

Read more »

money goes up and down in balance
Dividend Stocks

2 Incredibly Cheap Growth Stocks to Buy Now

These two growth stocks are both unbelievably cheap and have significant long-term potential, making them some of the best to…

Read more »

A cannabis plant grows.
Stocks for Beginners

1 Canadian Cannabis Stock Down 57% to Buy Now for Future Growth

Cannabis stocks might seem so 2018, but this one could eventually make a major comeback.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

Buy the Dip Before It’s Too Late: This Canadian Stock Won’t Stay Cheap Forever

Investors might think that cannabis stocks are out, but this one could be the top Canadian stock to consider.

Read more »

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »